Huff M W, Telford D E, Barrett P H, Billheimer J T, Gillies P J
Department of Medicine, University of Western Ontario, London, Canada.
Arterioscler Thromb. 1994 Sep;14(9):1498-508. doi: 10.1161/01.atv.14.9.1498.
To test the hypothesis that hepatic cholesteryl ester is involved in the regulation of apolipoprotein (apo) B secretion into plasma, apoB kinetic studies were performed in six control miniature pigs and in six pigs after a 21-day administration of the acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor DuP 128 (2.2 mg.kg-1.d-1 i.v.). Pigs were fed low-fat, cholesterol-free diets. Total plasma cholesterol, triglyceride, very-low-density lipoprotein (VLDL) triglyceride, and low-density lipoprotein (LDL) cholesterol decreased 18%, 29%, 40%, and 26% respectively (P < .03). 131I-VLDL and 125I-LDL were injected simultaneously into each animal, and apoB kinetics were analyzed by using multi-compartmental analysis (SAAM30). VLDL apoB pool size decreased significantly by 60% (0.32 versus 0.84 mg/kg), which was due to a 65% reduction in the VLDL apoB production or secretion rate (1.03 versus 2.94 mg.kg-1.h-1). The fractional catabolic rate was unchanged. LDL apoB pool size decreased nonsignificantly by 18% (5.61 versus 6.90 mg/kg) due entirely to a 24% decrease in production rate (0.26 versus 0.34 mg.kg-1.h-1). At necropsy, hepatic microsomal ACAT activity decreased by 68% (0.28 versus 0.88 nmol.min-1.mg-1; P < .0002). Although an increase in hepatic free cholesterol leading to a decreased LDL receptor expression might be expected, this did not occur. The concentration of hepatic cholesterol and the LDL apoB fractional catabolic rate were unaffected by DuP 128. In addition, the concentration of hepatic triglyceride and the activity of diacylglycerol acyltransferase were not altered by DuP 128, indicating a lack of effect of DuP 128 on hepatic triglyceride metabolism. We conclude that inhibition of hepatic cholesteryl ester synthesis in vivo decreases apoB secretion into plasma.
为验证肝胆固醇酯参与调节载脂蛋白(apo)B分泌入血浆这一假说,在6只对照小型猪及6只经21天静脉注射酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂DuP 128(2.2mg·kg⁻¹·d⁻¹)的猪身上进行了apoB动力学研究。猪被喂食低脂、无胆固醇饮食。总血浆胆固醇、甘油三酯、极低密度脂蛋白(VLDL)甘油三酯和低密度脂蛋白(LDL)胆固醇分别下降了18%、29%、40%和26%(P <.03)。将¹³¹I-VLDL和¹²⁵I-LDL同时注入每只动物体内,并使用多室分析(SAAM30)分析apoB动力学。VLDL apoB池大小显著下降60%(从0.84mg/kg降至0.32mg/kg),这是由于VLDL apoB产生或分泌速率降低了65%(从2.94mg·kg⁻¹·h⁻¹降至1.03mg·kg⁻¹·h⁻¹)。分解代谢分数率未改变。LDL apoB池大小非显著下降18%(从6.90mg/kg降至5.61mg/kg),完全是由于产生速率下降了24%(从0.34mg·kg⁻¹·h⁻¹降至0.26mg·kg⁻¹·h⁻¹)。尸检时,肝微粒体ACAT活性下降了68%(从0.88nmol·min⁻¹·mg⁻¹降至0.28nmol·min⁻¹·mg⁻¹;P <.0002)。尽管预计肝游离胆固醇增加会导致LDL受体表达下降,但并未出现这种情况。肝胆固醇浓度和LDL apoB分解代谢分数率不受DuP 128影响。此外,肝甘油三酯浓度和二酰甘油酰基转移酶活性未被DuP 128改变,表明DuP 128对肝甘油三酯代谢无影响。我们得出结论,体内抑制肝胆固醇酯合成会减少apoB分泌入血浆。